These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
169 related items for PubMed ID: 6722832
1. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration. Struck RF, Alberts DS. Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832 [Abstract] [Full Text] [Related]
2. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Sladek NE, Doeden D, Powers JF, Krivit W. Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951 [Abstract] [Full Text] [Related]
3. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ. Cancer Res; 1987 May 15; 47(10):2723-6. PubMed ID: 3552204 [Abstract] [Full Text] [Related]
4. Investigation on cyclophosphamide treatment during the preimplantation period. II. In vitro studies on the effects of cyclophosphamide and its metabolites 4-OH-cyclophosphamide, phosphoramide mustard, and acrolein on blastulation of four-cell and eight-cell mouse embryos and on their subsequent development during implantation. Spielmann H, Jacob-Müller U. Teratology; 1981 Feb 15; 23(1):7-13. PubMed ID: 7245091 [Abstract] [Full Text] [Related]
5. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry. Momerency G, Van Cauwenberghe K, Slee PH, Van Oosterom AT, De Bruijn EA. Biol Mass Spectrom; 1994 Mar 15; 23(3):149-58. PubMed ID: 8148406 [Abstract] [Full Text] [Related]
6. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Chan KK, Hong PS, Tutsch K, Trump DL. Cancer Res; 1994 Dec 15; 54(24):6421-9. PubMed ID: 7987837 [Abstract] [Full Text] [Related]
7. Half-life of oxazaphosphorines in biological fluids. Sladek NE, Powers JF, Grage GM. Drug Metab Dispos; 1984 Dec 15; 12(5):553-9. PubMed ID: 6149904 [Abstract] [Full Text] [Related]
8. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Hemminki K. Cancer Res; 1985 Sep 15; 45(9):4237-43. PubMed ID: 4028012 [Abstract] [Full Text] [Related]
9. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Struck RF, Kirk MC, Witt MH, Laster WR. Biomed Mass Spectrom; 1975 Feb 15; 2(1):46-52. PubMed ID: 1131393 [Abstract] [Full Text] [Related]
10. Effect of phenobarbital on plasma levels of cyclophosphamide and its metabolites in the mouse. Alberts DS, Peng YM, Chen HS, Struck RF. Br J Cancer; 1978 Aug 15; 38(2):316-24. PubMed ID: 698048 [Abstract] [Full Text] [Related]
11. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Eur J Cancer; 2011 Jul 15; 47(10):1556-63. PubMed ID: 21482104 [Abstract] [Full Text] [Related]
12. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Jardine I, Fenselau C, Appler M, Kan MN, Brundrett RB, Colvin M. Cancer Res; 1978 Feb 15; 38(2):408-15. PubMed ID: 620410 [Abstract] [Full Text] [Related]
13. Identification and quantitation of alcophosphamide, a metabolite of cyclophosphamide, in the rat using chemical ionization mass spectrometry. Hong PS, Chan KK. Biomed Environ Mass Spectrom; 1987 Apr 15; 14(4):167-72. PubMed ID: 2954602 [Abstract] [Full Text] [Related]
14. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat. Hong PS, Srigritsanapol A, Chan KK. Drug Metab Dispos; 1991 Apr 15; 19(1):1-7. PubMed ID: 1673381 [Abstract] [Full Text] [Related]
15. Cyclophosphamide metabolism in children. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR. Cancer Res; 1995 Feb 15; 55(4):803-9. PubMed ID: 7850793 [Abstract] [Full Text] [Related]
16. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Hadidi AH, Coulter CE, Idle JR. Cancer Res; 1988 Sep 15; 48(18):5167-71. PubMed ID: 3409242 [Abstract] [Full Text] [Related]
17. Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, Wolf CR. Cancer Res; 2005 May 15; 65(10):4211-7. PubMed ID: 15899812 [Abstract] [Full Text] [Related]
18. Effects of phosphoramide mustard and acrolein, cytotoxic metabolites of cyclophosphamide, on mouse limb development in vitro. Hales BF. Teratology; 1989 Jul 15; 40(1):11-20. PubMed ID: 2763206 [Abstract] [Full Text] [Related]
19. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. Yu LJ, Drewes P, Gustafsson K, Brain EG, Hecht JE, Waxman DJ. J Pharmacol Exp Ther; 1999 Mar 15; 288(3):928-37. PubMed ID: 10027828 [Abstract] [Full Text] [Related]
20. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats. Fetting JH, McCarthy LE, Borison HL, Colvin M. Cancer Treat Rep; 1982 Aug 15; 66(8):1625-9. PubMed ID: 7105052 [Abstract] [Full Text] [Related] Page: [Next] [New Search]